Amlodipine/Losartan/Rosuvastatin/Ezetimibe

氨氯地平/氯沙坦/瑞舒伐他汀/依折麦布

Report date: 2025/03/17 20:00:36

Base Information

Drug NameAmlodipine/Losartan/Rosuvastatin/Ezetimibe
Drug Alias NameAmlodipine+Losartan+Rosuvastatin+Ezetimibe氨氯地平+氯沙坦+瑞舒伐他汀+依泽替米贝HGP-0904+HGP-0608+HCP-1306HCP-1701
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockersHMG-CoA reductase inhibitors +[5] 
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channelHMG-CoA reductase +[4] 
Therapy Area/IndicationsDyslipidemiasHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Losartan PotassiumAmlodipine BesylateEzetimibe
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHanmi Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDyslipidemiasHypertension

Other Information

ATC CodeN/A
Related LinksN/A